Full Length Research Paper
References
|
Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G (2017). Factors associated with virological non-suppression among HIV positive patients on antiretroviral therapy in Uganda, August 2014-July 2015. BMC Infectious Diseases. 17(1):1-11. |
|
|
Carrieri MP, Raffi F, Lewden C (2003). Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antiviral Therapy 8:585-594. |
|
|
Craw JA, Beer L, Tie Y, Jaenicke T, Shouse RL, Prejean J (2020). Viral rebound among persons diagnosed with HIV who achieved viral suppression, United States. Journal of Acquired Immune Deficiency Syndromes 84(2):133-140. |
|
|
De Bruin M, Oberjé EJM, Viechtbauer W, Nobel HE, Hiligsmann M, van Nieuwkoop C (2017). Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial. Lancet Infectious Diseases 17(6):595-604. |
|
|
Henrich TJ, Wood BR, Kuritzkes DR (2012). Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/ml. PLoS ONE 7(11):e50065. |
|
|
Lima VD, Hogg RS, Harrigan PR (2007). Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21:685-892. |
|
|
Mainaa EK, Mureithia H, Adana AA, Muriukib J, Lwembeb RM, Bukusia EA (2020). Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. International Journal of Infectious Diseases 97(1):151-158 |
|
|
Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N (2016). Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. AIDS Research and Human Retroviruses 32(2):148-154. |
|
|
National Committee for the Fight against AIDS (2023-2027). National strategic plan to combat HIV and AIDS in the Central African Republic. |
|
|
O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M (2017). Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV 4(7):e295-302. |
|
|
Opoku S, Asamoah Sakyi S, Kwame Ayisi Boateng N, Kwame Enimil A, Senu E, Owusu Ansah R (2022). Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. AIDS Research and Therapy 19:21. |
|
|
Palmer A, Gabler K, Rachlis B, Ding E, Chia J, Bacani N (2018). Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine 97(22):e10562. |
|
|
Taner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A (2016). Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infectious Diseases 16:590. |
|
|
UNAIDS (2022). Global AIDS Update Report 2022. License: CC BY-NC-SA 3.0 IGO. |
|
|
World Health Organization (WHO) (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization. License: CC BY-NC-SA 3.0 IGO. |
|
|
World Health Organization (WHO) (2017). Key considerations for differentiated delivery of antiretroviral treatments to special populations: children, adolescents, pregnant or lactating women and key populations. Geneva: World Health Organization; (WHO/HIV/2017.34). License: CC BY-NC-SA 3.0 IGO. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
